Medical Policy
Policy Num: 08.003.006
Policy Name: Cardiac Rehabilitation in the Outpatient Setting
Policy ID: [08.003.006] [Ac / B / M+ / P+] [8.03.08]
Last Review: April 09, 2024
Next Review: April 20, 2025
Related Policies: None
Cardiac Rehabilitation in the Outpatient Setting
Reference No. | Populations | Interventions | Comparators | Outcomes |
1 | Individuals:
| Interventions of interest are:
| Comparators of interest are:
| Relevant outcomes include:
|
2 | Individuals:
| Interventions of interest are:
| Comparators of interest are:
| Relevant outcomes include:
|
3 | Individuals:
| Interventions of interest are:
| Comparators of interest are:
| Relevant outcomes include:
|
4 | Individuals:
| Interventions of interest are:
| Comparators of interest are:
| Relevant outcomes include:
|
5 | Individuals:
| Interventions of interest are:
| Comparators of interest are:
| Relevant outcomes include:
|
6 | Individuals:
| Interventions of interest are:
| Comparators of interest are:
| Relevant outcomes include:
|
7 | Individuals:
| Interventions of interest are:
| Comparators of interest are:
| Relevant outcomes include:
|
SUMMARY
Cardiac rehabilitation refers to comprehensive medically supervised programs in the outpatient setting that aim to improve the function of patients with heart disease and prevent future cardiac events. National organizations have specified core components to be included in cardiac rehabilitation programs.
For individuals who have been diagnosed with heart disease and receive outpatient cardiac rehabilitation, the evidence includes multiple randomized controlled trials (RCTs) and systematic reviews of these trials. Relevant outcomes are overall survival (OS), disease-specific survival, symptoms, and morbid events. Meta-analyses of the available trials have found that cardiac rehabilitation improves health outcomes for select patients, particularly those with coronary heart disease, heart failure, and who have had cardiac surgical interventions. The available evidence has limitations, including lack of blinded outcome assessment, but for the survival-related outcomes of interest, this limitation is less critical. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
For individuals who have been diagnosed with heart disease without a second event and receive repeat outpatient cardiac rehabilitation, the evidence includes no trials. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. No studies were identified evaluating the effectiveness of repeat participation in a cardiac rehabilitation program. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
For individuals who have been diagnosed with heart disease and receive intensive cardiac rehabilitation with the Ornish Program for Reversing Heart Disease, the evidence includes an RCT. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. No RCTs have compared the Ornish Program with a “standard” cardiac rehabilitation program; an RCT compared it with usual care. The trial included patients with coronary artery disease and no recent cardiac events and had mixed findings at 1 and 5 years. The trial had a small sample size for a cardiac trial (N=48), and only 35 patients were available for the 5-year follow-up. The Ornish Program is considered by the Centers for Medicare & Medicaid Services as an intensive cardiac rehabilitation program, but the program described in the RCT could meet criteria for standard cardiac rehabilitation. No studies were identified comparing the Ornish Program with any other cardiac rehabilitation program. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
For individuals who have been diagnosed with heart disease and receive intensive cardiac rehabilitation with the Pritikin Program, the evidence includes 2 nonrandomized studies. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. Studies are needed that compare the impact of intensive cardiac rehabilitation using the Pritikin Program with standard outpatient cardiac rehabilitation programs for these outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
For individuals who have been diagnosed with heart disease and receive intensive cardiac rehabilitation with the Benson-Henry Institute Program, the evidence includes a case-control study and case series. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. Studies are needed that compare the impact of intensive cardiac rehabilitation using the Benson-Henry Institute Program with standard outpatient cardiac rehabilitation programs. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
For individuals who have heart disease due to post-acute sequelae of SARS-CoV-2 infection who receive cardiac rehabilitation in the outpatient setting, no relevant evidence was identified. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. Limited reports examining the outcomes of rehabilitation in patients with post-acute COVID-19 have not primarily focused on cardiac rehabilitation. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
For individuals who have been diagnosed with heart disease and receive virtual cardiac rehabilitation, the evidence includes systematic reviews/meta-analyses, RCTs, and observationalr studies. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. Meta-analyses have found beneficial effects of virtual cardiac rehabilitation on physical activity and quality of life, but not on cardiovascular hospitalization or mortality. The few available prospective randomized studies have conflicting findings on the effect of virtual cardiac rehabilitation compared to traditional outpatient cardiac rehabilitation for hospital readmission. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Not applicable.
The objective of this evidence review is to determine whether outpatient cardiac rehabilitation programs improve the net health outcome in individuals with heart disease.
Outpatient cardiac rehabilitation programs may be considered medically necessary for individuals with a history of the following conditions and procedures:
acute myocardial infarction (heart attack) within the preceding 12 months;
coronary artery bypass graft surgery;
percutaneous transluminal coronary angioplasty or coronary stenting;
heart valve surgery;
heart or heart-lung transplantation;
current stable angina pectoris; or
compensated heart failure.
Repeat participation in an outpatient cardiac rehabilitation program in the absence of another qualifying cardiac event is considered investigational.
Intensive cardiac rehabilitation with the Ornish Program for Reversing Heart Disease, Pritikin Program, or Benson-Henry Institute Program is considered investigational.
Virtual cardiac rehabilitation is considered investigational.
Outpatient cardiac rehabilitation is considered investigational for all other indications (e.g., SARS-CoV-2).
The following components must be included in cardiac rehabilitation programs:
physician-prescribed exercise each day cardiac rehabilitation services are provided;
cardiac risk factor modification;
psychosocial assessment;
outcomes assessment; and
an individualized treatment plan detailing how each of the above components are utilized.
A cardiac rehabilitation exercise program is eligible for coverage for 3 sessions per week up to a 12-week period (36 sessions). Programs should start within 90 days of the cardiac event and be completed within 6 months of the cardiac event.
A comprehensive evaluation may be performed before the initiation of cardiac rehabilitation to evaluate the individual and determine an appropriate exercise program. In addition to a medical examination, an electrocardiogram stress test may be performed. An additional stress test may be performed at the completion of the program.
Physical and/or occupational therapy are not medically necessary in conjunction with cardiac rehabilitation unless performed for an unrelated diagnosis.
See the Codes table for details.
Cardiac rehabilitation must be performed in a facility approved by the Plan. A single initial visit with the physician for a referral to a program may be allowed under CPT code 99215.
Services that are educational in nature (eg, lectures or counseling), which are performed as part of the cardiac rehabilitation program, are not eligible for coverage, even when occurring on a different date of service unless specified in the contract or certificate of coverage.
Psychological testing and psychotherapy are not usual components of cardiac rehabilitation. Such services for patients who have a psychiatric diagnosis must be considered under the Mental Health Benefits of the contract.
The ongoing maintenance program that follows the 12-week rehabilitation program is not eligible for coverage.
Some contracts have an exclusion for cardiac rehabilitation because this is considered “self-care” or “self-help” training. In these cases, any related diagnostic testing must also be excluded.
Benefits are determined by the group contract, member benefit booklet, and/or individual subscriber certificate in effect at the time services were rendered. Benefit products or negotiated coverages may have all or some of the services discussed in this medical policy excluded from their coverage
Heart disease is the leading cause of mortality in the United States, accounting for more than half of all deaths. Coronary artery disease is the most common cause of heart disease. In a 2024 update on heart disease and stroke statistics from the American Heart Association, it was estimated that 720,000 Americans have a new coronary attack (first hospitalized myocardial infarction or coronary heart disease death) and 335,000 have a recurrent attack annually.1, Both coronary artery disease and various other disorders—structural heart disease and other genetic, metabolic, endocrine, toxic, inflammatory, and infectious causes—can lead to the clinical syndrome of heart failure, of which there are about 650,000 new cases in the United States annually.2, Given the burden of heart disease, preventing secondary cardiac events and treating the symptoms of heart disease and heart failure have received much attention from national organizations.
In 1995, the U.S. Public Health Service defined cardiac rehabilitation services as, in part, “comprehensive, long-term programs involving medical evaluation, prescribed exercise, cardiac risk factor modification, education, and counseling…. [These programs] are designed to limit the physiologic and psychological effects of cardiac illness, reduce the risk for sudden death or reinfarction, control cardiac symptoms, stabilize or reverse the atherosclerotic process, and enhance the psychosocial and vocational status of selected patients.” The U.S. Public Health Service recommended cardiac rehabilitation services for patients with coronary heart disease and heart failure, including those awaiting or following cardiac transplantation. A 2010 definition of cardiac rehabilitation from the European Association of Cardiovascular Prevention and Rehabilitation stated: “Cardiac rehabilitation can be viewed as the clinical application of preventive care by means of a professional multi-disciplinary integrated approach for comprehensive risk reduction and global long-term care of cardiac patients.”3, Since the 1995 release of the U.S. Public Health Service guidelines, other societies, including in 2005 the American Heart Association4, and in 2010 the Heart Failure Society of America 5, have developed guidelines on the role of cardiac rehabilitation in patient care.
Not applicable.
RATIONALE
This evidence review was created in May 1997, archived from 2003 to 2010, and since its return to active review, it has been updated regularly with searches of the PubMed database. The most recent literature update was performed through January 23, 2024.
Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.
To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and the quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.
Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.
The purpose of cardiac rehabilitation in individuals who have heart disease is to provide a treatment option that is an alternative to or an improvement on existing therapies.
The following PICO was used to select literature to inform this review.
The relevant population of interest is individuals with diagnosed heart disease.
The treatment being considered is cardiac rehabilitation. Cardiac rehabilitation includes long-term programs that include medical evaluation, prescribed exercise, modification to reduce cardiac risks, education, and counseling.
The comparator of interest is standard management without cardiac rehabilitation. The following practices are currently being used to manage heart disease: medication, surgery, and medical devices.
The general outcomes of interest are overall survival (OS), disease-specific survival, symptoms, and morbid events.
Once diagnosed with heart disease, a patient will require lifelong monitoring by a cardiologist.
Methodologically credible studies were selected using the following principles:
To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.
Oldridge (2012) identified 6 independent meta-analyses published since 2000 that reported outcomes from 71 RCTs (N=13,824) following cardiac rehabilitation interventions.6, The RCTs included in the meta-analyses enrolled patients with myocardial infarction, coronary heart disease, angina, percutaneous coronary intervention (PCI), and/or coronary artery bypass graft (CABG). The RCTs compared cardiac rehabilitation programs (exercise-only and/or comprehensive rehabilitation) with usual care. Cardiac rehabilitation was associated with a statistically significant (p<.05) reduction in all-cause mortality in 4 of the 5 meta-analyses that reported this outcome. In the pooled analysis, cardiac rehabilitation was associated with an 18.5% mean reduction in all-cause mortality. Also, cardiac rehabilitation was associated with a statistically significant reduction in cardiac mortality in 3 of the 4 meta-analyses that reported disease-specific mortality as an outcome.
Two of the meta-analyses on cardiac rehabilitation were Cochrane reviews. One included patients with coronary heart disease.7, and the other focused on patients with systolic heart failure.8, Both addressed exercise-based cardiac rehabilitation programs (exercise alone or as part of a comprehensive program). Anderson et al (2016) updated a 2011 Cochrane review addressing exercise-based cardiac rehabilitation for individuals with coronary heart disease.7,9, Reviewers included RCTs of exercise-based interventions with at least 6 months of follow-up compared with no-exercise controls in patients with myocardial infarction, CABG, or PCI, or with angina pectoris or coronary artery disease. The updated review included 63 RCTs (N=14,486), of which 16 trials had been published since the 2011 update. Reviewers reported that the overall risk of bias was unclear, although the quality of reporting improved with more recent trials. Due to the nature of the intervention, patients were not blinded to the treatment group in any of the studies, but 16 (25%) of 62 studies reported details of blinded assessment of study outcomes. In the pooled analysis, cardiac rehabilitation was not significantly associated with overall mortality. However, among 27 studies, cardiac rehabilitation was significantly associated with reduced cardiovascular mortality (292/3850 for cardiac rehabilitation subjects vs. 375/3,619 for control subjects; relative risk [RR], 0.74; 95% confidence interval [CI], 0.64 to 0.86). Rates of myocardial infarction, CABG, and PCI were not significantly associated with receiving cardiac rehabilitation.
Long et al (2019) reported a Cochrane Review of studies assessing cardiac rehabilitation in patients with heart failure. A total of 44 RCTs were evaluated,11 of which were new trials, for the effects of exercise-based cardiac rehabilitation on adults with heart failure (5,783 total participants).10, A single trial, Exercise Based Cardiac Rehabilitation for Adults With Heart Failure (HF-ACTION), contributed almost half of the patients (with results reported in 18 publications); most other studies were small and single-center. All studies had 6 months or longer follow-up and did not include a formal exercise training intervention as a comparator. The primary outcomes reported were mortality, hospital admission, and health-related quality of life (HRQoL). The overall risk of bias was assessed as being low or unclear, and results were downgraded using the GRADE tool for all outcomes except one. Results showed that cardiac rehabilitation had little effect on all-cause mortality over ≤1 year of follow-up (27 trials, 2,596 participants: cardiac rehabilitation 5.1% vs. control 5.8%; low-quality evidence). However, cardiac rehabilitation may make a difference in the long-term (>1 year of follow-up; 6 trials, 2,845 participants: cardiac rehabilitation 17.2% vs. control 19.6%; high-quality evidence). Mortality related to heart failure was not consistently reported in the studies. Chances of avoiding hospital admission for any cause within 12 months of follow-up were better with cardiac rehabilitation (21 trials, 2,182 participants: cardiac rehabilitation 16.5% vs. control 23.7%; moderate-quality evidence). Cardiac rehabilitation may also reduce short-term heart failure-related hospital admission (14 trials, 1,114 participants: cardiac rehabilitation 7.1% vs. control 11.1%; RR, 0.59, 95% CI, 0.42 to 0.84; p=.003), but the evidence was rated low quality. HRQoL was reported by 29 trials, most of which used the Minnesota Living With Heart Failure questionnaire; however, other tools were also used among the 29 trials that reported validated HRQoL measures. For exercise-based cardiac rehabilitation, no trials reported lower HRQoL scores with cardiac rehabilitation than with control, and all but 1 reported on results at ≥6 months follow-up. The pooled results from all measures used showed a clinically important improvement (a 5-point difference on the Minnesota Living With Heart Failure) with exercise at up to 12 months follow-up, but the evidence was of very low quality. Compared with the 2014 review, this version included more women, older patients, participants with heart failure with preserved ejection fraction in recent trials, and more trials of cardiac rehabilitation in a home-based setting; this version may be more valid and applicable. A 2023 update by Molloy et al identified 16 new trials. Improvements in all-cause mortality, all-cause hospitalization, and HF-related hospitalization were noted with cardiac rehabilitation in any setting compared with usual care; however, the improvements were only significant for all-cause hospitalization in the short term (RR, 0.69, 95% CI, 0.56-0.86).11,
Study | Dates | Trials | Participants | N (Range) | Design |
---|---|---|---|---|---|
Davies et al (2010)8, | 1995-2008 | 29 | All adults with chronic systolic HF | 3647 (20 to 2331) | RCT |
Oldridge (2012)6, | 2000-2011 | 71 | Patients with MI, CHD, angina, PCI, and/or CABG | 13,824 (6,111 to 10,794) | RCT |
Anderson et al (2016)7, | 1975-2014 | 63 | Patients with MI, angina pectoris, CAD, or who underwent CABG or PCI | 14,486 (25 to 3184) | RCT |
Long et al (2019)10, | 1995-2018 | 44 | Patients with HF | 5783 (19 to 2331) | RCT |
Molloy et al (2023)11, | Through December 2021 | 60 | Patients with HF | 8728 (NR) | RCT |
CABG: coronary artery bypass graft; CAD: coronary artery disease; CHD: coronary heart disease; HF: heart failure; MI: myocardial infarction; PCI: percutaneous coronary intervention; RCT: randomized controlled trial.
Table 2. Systematic Review Results
Study | All-Cause Mortality | Cardiovascular Mortality |
---|---|---|
Davies et al (2010)8, | 13 studies (≤12 mo) | NR |
Difference in pooled mortality, fixed-effect RR | 1.02 | NR |
95% CI | 0.70 to 1.51 | NR |
p-value | .90 | NR |
Oldridge (2012)6, | 6 studies | 6 studies |
Reduction, mean % | 18.50 | 29.4 |
p-value | <.05 | NR |
Range, % | NR | 20 to 43 |
Anderson et al (2016)7, | 47 studies; N=12,455 participants | 27 studies; N=7469 participants |
RR | 0.96 | 0.74 |
95% CI | 0.88 to 1.04 | 0.64 to 0.86 |
Long et al (2019)10, | 2845 participants, 6 studies | (studies did not consistently report deaths due to heart failure) |
RR | 0.88 | NR |
95% CI | 0.75 to 1.02 | NR |
Molloy et al (2023)11, | 3780 participants, 8 studies | NR |
RR | 0.87 (long-term, >12 months) | NR |
95% CI | 0.72 to 1.04 | NR |
CI: confidence interval; NR: not reported; RR: relative risk.
Randomized Controlled Trials
Findings of a large, multicenter RCT from the United Kingdom, which evaluated the effectiveness of cardiac rehabilitation in a “real-life” setting, were published by West et al (2012).12, Called the Rehabilitation After Myocardial Infarction Trial (RAMIT), the study included patients from 14 centers with established multifactorial cardiac rehabilitation programs (including exercise, education, and counseling), involved more than 1 discipline, and provided an intervention lasting a minimum of 10 hours. A total of 1,813 patients were randomized: 903 to cardiac rehabilitation and 910 to a control condition. Vital status was obtained at 2 years for 99.9% (all but 1 patient) and at 7 to 9 years for 99.4% of patients. By 2 years, 166 patients had died: 82 in the cardiac rehabilitation group and 84 in the control group. The between-group difference in mortality at 2 years (the primary study outcome) was not statistically significant (RR, 0.98; 95% CI, 0.74 to 1.30). After 7 to 9 years, 488 patients had died, 245 in the cardiac rehabilitation group and 243 in the control group (RR, 0.99; 95% CI, 0.85 to 1.15). In addition, at 1 year, cardiovascular morbidity did not differ significantly between groups. For a combined endpoint including death, nonfatal myocardial infarction, stroke, or revascularization, the RR was 0.96 (95% CI, 0.88 to 1.07). In discussing the study’s negative findings, trialists noted that medical management of heart disease had improved over time, and patients in the control group might have had better outcomes than in earlier RCTs on this topic. Moreover, an editorial accompanying the publication of the trial’s findings emphasized that RAMIT was not an efficacy trial, but rather, a trial evaluating the effectiveness of actual cardiac rehabilitation programs in the United Kingdom.13, Finally, these results might in part reflect the degree to which clinically-based cardiac rehabilitation programs in the United Kingdom differ from the treatment protocols used in RCTs based in research settings.
A concern raised by the negative findings in the RAMIT trial is that most of the RCTs evaluating cardiac rehabilitation were conducted in an earlier era of heart disease management and might not be relevant to current care. However, RAMIT’s results, along with 15 additional RCTs reported since a 2011 Cochrane review, were included in the updated 2016 Cochrane review, which found improvements in cardiovascular mortality associated with exercise-based cardiac rehabilitation.
Pandey et al (2017) evaluated endurance exercise training as part of a cardiac rehabilitation program in a population of heart failure patients stratified by ejection fraction.14, Participants had heart failure with preserved ejection fraction or reduced ejection fraction, were 65 years of age or older, and had participated in a 16-week exercise program that intensified from 40% to 50% of heart rate reserve in the first 2 weeks to 60% to 70% over the ensuing weeks as part of a previously published RCT.15, The primary outcome for assessing change in exercise capacity was the percentage change in peak oxygen uptake (mL/kg per minute) from baseline to end of exercise training (16-week follow-up). Data on testing from 48 patients (24 reduced ejection fraction, 24 heart failure with preserved ejection fraction) were assessed. Heart failure with preserved ejection fraction patients experienced greater improvement in exercise training patients (18.7%) than reduced ejection fraction patients (-0.3%; p<.001) as measured by peak oxygen uptake. There was no information on subsequent hospitalization rates or clinical outcomes such as heart failure progression or mortality. This secondary analysis was used to assert the appropriateness of cardiac rehabilitation in heart failure with preserved ejection fraction patients.
Opotowsky et al (2018) compared cardiac rehabilitation to the standard of care in 28 subjects (mean age: 41.1 years) with moderate to severe congenital heart disease.16, Cardiac rehabilitation was associated with a significant increase in peak oxygen consumption with no associated adverse events. There was also a nonsignificant improvement in peak work rate with cardiac rehabilitation as compared to standard of care (p=.16) and a significant improvement in self-assessment of overall health (p<.04). However, the study was limited by its small sample size and short-term follow-up.
Tables 3 and 4 provide a summary of key RCT characteristics and results.
Trial | Countries | Sites | Dates | Participants | Interventions | |
---|---|---|---|---|---|---|
Active | Comparator | |||||
West et al (2012); RAMIT12, | United Kingdom | 14 | 1997-2000 | Patients diagnosed with acute MI (N=1813) | Cardiac rehabilitation (n=903) | Control (n=910) |
Pandey et al (2017)14, | U.S. | 1 | NR | Patients aged ≥65 years with HFrEF (n=24) or HFpEF (n=24) | 16-wk supervised moderate endurance exercise training (n=48) | HRrEF (n=24) vs. HFpEF (n=24) |
Opotowsky et al (2018)16, | U.S. | 1 | NR | Patients aged ≥16 years with moderate to severe congenital heart disease (N=28) | 12-wk cardiac rehabilitation (n=13) | Standard of care (n=15) |
HF: heart failure; HFpEF: HF with preserved ejection fraction; HFrEF: HF with reduced ejection fraction; MI: myocardial infarction; NR: not reported; RCT: randomized controlled trial; RAMIT: Rehabilitation After Myocardial Infarction Trial.
Table 4. Summary of Key Randomized Controlled Trial Results
Study | 2-yr Mortality | Readmission to Hospital for Any Cardiac Condition at 1 y | Training-Related Improvement in Vo2 peak Change |
---|---|---|---|
West et al (2012); RAMIT12, | N=1,813 participants | N=1,813 participants | NR |
CR | 82 patients | 222 (25%) | NR |
Control | 84 patients | 239 (26%) | NR |
RR | 0.98 | NR | NR |
95% CI | 0.74 to 1.30 | NR | NR |
Pandey et al (2017)14, | NR | NR | N=48 participants |
HFrEF | NR | NR | 18.7+/-17.6 |
HFpEF | NR | NR | -0.3+/-15.4 |
p-value | NR | NR | <.001 |
Opotowsky et al (2018)16, | N=28 participants | ||
CR | NR | NR | +2.2 mL/kg/min (compared to standard of care) |
95% CI; p-value | NR | NR | 0.7 to 3.7; p=.002 |
CI: confidence interval; CR: cardiac rehabilitation; HF: heart failure; HFpEF: HF with preserved ejection fraction; HFrEF: HF with reduced ejection fraction; NR: not reported; RCT: randomized controlled trial; RR: relative risk; Vo2peak: peak oxygen uptake. RAMIT: Rehabilitation After Myocardial Infarction Trial.
The purpose of the limitations tables (see Tables 5 and 6) is to display notable limitations identified in each study. This information is synthesized as a summary of the body of evidence following each table and provides the conclusions on the sufficiency of the evidence supporting the position statement.
Study | Populationa | Interventionb | Comparatorc | Outcomesd | Follow-Upe |
---|---|---|---|---|---|
West et al (2012); RAMIT12, | 4,5. Descriptions of diversity in study populations were not reported | 1,2. Trial was closed prematurely | |||
Pandey et al (2017)14, | 4. Enrolled populations do not reflect relevant diversity; 81% of participants were White | 2. No comparator used | 1,2. Only 16 wks follow-up | ||
Opotowsky et al (2018)16, | 4,5. Descriptions of diversity in study populations were not reported | 1. Key health outcomes such as mortality or readmission not addressed | 1,2. Only 12 wks follow-up |
RAMIT: Rehabilitation After Myocardial Infarction Trial.
The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.
a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4, Enrolled populations do not reflect relevant diversity; 5. Other.
b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest. 5: Other.
c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively. 5: Other.
d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported. 7. Other.
e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms. 3. Other.
Study | Allocationa | Blindingb | Selective Reportingc | Follow-Upd | Powere | Statisticalf |
---|---|---|---|---|---|---|
West et al (2012); RAMIT12, | 3. Allocation concealment unclear | 1,2. Not blinded | ||||
Pandey et al (2017)14, | 1. Participants not randomly allocated | 1,2. Not blinded | ||||
Opotowsky et al (2018)16, | 1,2. Not blinded | 1. Power calculations not reported |
RAMIT: Rehabilitation After Myocardial Infarction Trial.
The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps s assessment.
a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.
b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.
c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.
d Follow-Up key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).
e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.
f Statistical key: 1. Intervention is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Intervention is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.
Sumner et al (2017) published a systematic review of controlled observational studies evaluating cardiac rehabilitation in patients diagnosed with acute myocardial infarction.17, Cardiac rehabilitation interventions consisted of structured multicomponent programs that included exercise and at least 1 of the following: education, information, health behavior change, and psychological or social support. Usual care interventions, generally supervised medical interventions, were the control conditions. Ten studies met reviewers’ eligibility criteria. In a meta-analysis of 5 studies reporting all-cause mortality (an unadjusted outcome), there was a significantly lower risk of death in the group that received cardiac rehabilitation (odds ratio [OR], 0.25; 95% CI, 0.16 to 0.40). Three studies that reported an adjusted analysis of all-cause mortality also found a significant benefit from cardiac rehabilitation (OR, 0.47; 95% CI, 0.38 to 0.59). Similarly, a meta-analysis of 3 studies reporting cardiac-related mortality (an unadjusted analysis) found a significant benefit from cardiac rehabilitation (OR, 0.21; 95% CI, 0.12 to 0.37). Only 1 study reported an adjusted analysis of cardiac-related mortality, so data could not be pooled.
Nilsson et al (2018) investigated the effect of a 12-week cardiac rehabilitation program with a high-intensity interval exercise component using participant peak oxygen uptake as a measure of improved exercise capacity.18, Increased exercise capacity has been shown to improve survival among persons with coronary heart disease. The objective of the study was to assess whether this addition to a cardiac rehabilitation program yielded improved long-term results. One hundred thirty-three coronary patients participated in this prospective cohort study and were evaluated at baseline, at the end of the 12-week program, and again at a 15-month follow-up. Additional test measurements included a cardiopulmonary exercise test, body mass index, blood pressure tests, and quality of life questionnaire. Of the 133 patients, 86 patients had complete information for the 15-month follow-up. Mean peak oxygen uptake improved from a baseline of 31.9 mL/kg/min to 35.9 mL/kg/min (p<.001) at the end of the 12-week program, and to 36.8 mL/kg/min (CI not reported) at 15-month follow-up. Most of the 86 patients reported maintaining an exercise routine. Study limitations included the small sample size, a relatively low-risk male population at baseline, and lack of information on the qualifying event for cardiac rehabilitation. The authors concluded that the cardiac rehabilitation program intervention potentially fostered consistent and beneficial exercise habits as demonstrated by improved peak oxygen uptake.
Jafri et al (2021) conducted a retrospective cohort study to evaluate home-based cardiac rehabilitation (HBCR) in patients with established cardiovascular disease.19, A total of 269 patients at a Veterans Affairs Medical Center were eligible for inclusion (HBCR group, n=157; non-HBCR control group, n=100); 12 patients were excluded due to having outcomes less than 90 days after enrollment (study follow-up period was between 3 to 12 months). A majority of patients (98%) were male, and the mean age was 72 years. The primary outcome was composite all-cause mortality and hospitalizations and secondary outcomes were all-cause hospitalization, all-cause mortality, and cardiovascular hospitalizations. The primary composite outcome occurred in both the HBCR (n=30) and control (n=30) (adjusted hazard ratio [HR], 0.56; 95% CI, 0.33 to 0.95; p=.03). All-cause mortality occurred in 6.4% of HBCR patients versus 13% of the control group (adjusted HR, 0.43; 95% CI, 0.18 to 1.0; p=.05). There was no difference in cardiovascular or all-cause hospitalizations between groups.
Overall, the evidence from RCTs reviewed in well-structured systematic reviews suggests that cardiac rehabilitation is associated with reduced cardiovascular mortality in patients with coronary heart disease. Additional RCTs, systematic reviews, and observational studies have evaluated outpatient cardiac rehabilitation in patients with heart failure or in the postintervention setting. An overview of 6 meta-analyses found a statistically significant association between cardiac rehabilitation and reduction in all-cause mortality and/or cardiac mortality. The available evidence has limitations, including lack of blinded outcome assessment, but, for the survival-related outcomes of interest, this limitation is less critical.
For individuals who have been diagnosed with heart disease and receive outpatient cardiac rehabilitation, the evidence includes multiple randomized controlled trials (RCTs) and systematic reviews of these trials. Relevant outcomes are overall survival (OS), disease-specific survival, symptoms, and morbid events. Meta-analyses of the available trials have found that cardiac rehabilitation improves health outcomes for select patients, particularly those with coronary heart disease, heart failure, and who have had cardiac surgical interventions. The available evidence has limitations, including lack of blinded outcome assessment, but for the survival-related outcomes of interest, this limitation is less critical. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.
Outpatient Cardiac Rehabilitation for Heart Disease
PopulationReference No. 1 Policy Statement | [X] Medically Necessary | [ ] Investigational |
Population Reference No. 2
The purpose of repeat cardiac rehabilitation in individuals who have heart disease without a second event is to provide a treatment option that is an alternative to or an improvement on existing therapies.
The following PICO was used to select literature to inform this review.
The relevant population of interest is individuals with diagnosed heart disease who have had cardiac rehabilitation before but who have not had a second cardiac event.
The treatment being considered is repeat cardiac rehabilitation. Cardiac rehabilitation includes long-term programs that include medical evaluation, prescribed exercise, modification to reduce cardiac risks, education, and counseling.
The comparator of interest is standard management with a single course of cardiac rehabilitation. Cardiac rehabilitation includes long-term programs that include medical evaluation, prescribed exercise, modification to reduce cardiac risks, education, and counseling.
The general outcomes of interest are OS, disease-specific survival, symptoms, and morbid events.
Once diagnosed with heart disease, a patient will require lifelong monitoring by a cardiologist.
Methodologically credible studies were selected using the following principles:
To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.
No studies were identified that evaluated the effectiveness of repeat participation in a cardiac rehabilitation program.
For individuals who have been diagnosed with heart disease without a second event who receive repeat outpatient cardiac rehabilitation, the evidence includes no trials.
There is no standard definition of an intensive cardiac rehabilitation program and, thus, specific programs are reviewed individually. Three programs have been evaluated by the Centers for Medicare & Medicaid Services, and the published evidence supporting these programs is reviewed. The ideal trial design would be an RCT comparing the impact of intensive cardiac rehabilitation with standard cardiac rehabilitation on health outcomes.
For individuals who have been diagnosed with heart disease without a second event and receive repeat outpatient cardiac rehabilitation, the evidence includes no trials. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. No studies were identified evaluating the effectiveness of repeat participation in a cardiac rehabilitation program. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Repeat Outpatient Cardiac Rehabilitation
PopulationReference No. 2 Policy Statement | [] Medically Necessary | [X] Investigational |
Population Reference No. 3
The purpose of the Ornish Program for Reversing Heart Disease in individuals who have been diagnosed with heart disease is to provide a treatment option that is an alternative to or an improvement on existing therapies.
The following PICO was used to select literature to inform this review.
The relevant population of interest is individuals with diagnosed heart disease.
The treatment being considered is the Ornish Program for Reversing Heart Disease.
The Ornish Program for Reversing Heart Disease is an intensive cardiac rehabilitation program that focuses on exercise, diet, stress management, and support from others.
The multiple 4-hour sessions are administered by an Ornish-certified physician, cardiac therapist, or other certified health care provider.
The comparator of interest is standard outpatient cardiac rehabilitation. Cardiac rehabilitation includes long-term programs that include medical evaluation, prescribed exercise, modification to reduce cardiac risks, education, and counseling.
The general outcomes of interest are OS, disease-specific survival, symptoms, and morbid events.
Once diagnosed with heart disease, a patient will require lifelong monitoring by a cardiologist.
Methodologically credible studies were selected using the following principles:
To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.
Ornish et al (1990) conducted an RCT, called the Lifestyle Heart Trial, comparing a version of the Ornish Program for Reversing Heart Disease with usual care. Initial results were reported in 1990, and 5-year results in 1998.20,21, Eligibility for the trial included diagnosed coronary artery disease, left ventricular ejection fraction greater than 25%, no myocardial infarction during the previous 6 weeks, not scheduled for CABG, and not taking lipid-lowering medication. Ninety-four eligible patients were randomized to an intervention group (n=53) or a usual care control group (n=43). Final consenting was done after randomization; 28 (53%) of patients assigned to the intervention group and 20 (43%) assigned to the control group agreed to participate in the trial.
The lifestyle intervention consisted of recommending a low-fat vegetarian diet and an individualized exercise regimen. Also, patients were taught stress management techniques and were taught to practice them at home for at least an hour a day. Also, twice-weekly group discussions were offered to provide social support. It is not clear how long patients attended these group discussions (ie, the number of weeks or months). As reported by Ornish et al (1990), the mean percentage diameter stenosis decreased from 40% at baseline to 37.8% at 1 year in the intervention group and increased from 42.7% to 46.1% in the control group (p=.001). The frequency and duration of chest pain did not differ between groups. However, during chest pain episodes, at 1 year, the intervention group reported mean chest pain severity of 1.7 (on a 7-point scale) whereas the mean score in the control group was 2.5 (p<.001).
Twenty (71%) of 28 patients in the intervention group and 15 (75%) of 20 in the control group completed the 5-year follow-up. The intervention and control groups did not differ significantly in the number of myocardial infarction events (2 vs. 4), CABGs (2 vs. 5), or deaths (2 vs. 1). However, compared with the control group, the intervention group had significantly fewer percutaneous transluminal coronary angioplasties (8 vs. 14 ; p<.050) and cardiac hospitalizations (23 vs. 44 ; p<.001).
One RCT was identified that evaluated the Ornish Program in patients diagnosed with heart disease and compared it with usual care. This RCT, which included patients with coronary artery disease but no recent cardiac event, had mixed findings at 1 and 5 years. The trial had a small sample size for a cardiac trial (N=48), and only 35 patients were available for the 5-year follow-up. The Ornish Program is considered by the Centers for Medicare & Medicaid Services to be an intensive cardiac rehabilitation program, but the program described in this RCT might meet the criteria for standard cardiac rehabilitation. No studies were identified that compared the Ornish Program with any other cardiac rehabilitation program.
For individuals who have been diagnosed with heart disease and receive intensive cardiac rehabilitation with the Ornish Program for Reversing Heart Disease, the evidence includes an RCT. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. No RCTs have compared the Ornish Program with a “standard” cardiac rehabilitation program; an RCT compared it with usual care. The trial included patients with coronary artery disease and no recent cardiac events and had mixed findings at 1 and 5 years. The trial had a small sample size for a cardiac trial (N=48), and only 35 patients were available for the 5-year follow-up. The Ornish Program is considered by the Centers for Medicare & Medicaid Services as an intensive cardiac rehabilitation program, but the program described in the RCT could meet criteria for standard cardiac rehabilitation. No studies were identified comparing the Ornish Program with any other cardiac rehabilitation program. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Ornish Program for Reversing Heart Disease
PopulationReference No. 3Policy Statement | [ ] Medically Necessary | [X] Investigational |
Population Reference No. 4
The purpose of the Pritikin Program in individuals who have been diagnosed with heart disease is to provide a treatment option that is an alternative to or an improvement on existing therapies.
The following PICO was used to select literature to inform this review.
The relevant population of interest is individuals with diagnosed heart disease.
The treatment being considered is the Pritikin Program.
The Pritikin Program is an intensive cardiac rehabilitation program based on effective exercise, a healthy diet, and a healthy mindset.
The comparator of interest is standard outpatient cardiac rehabilitation. Cardiac rehabilitation includes long-term programs that include medical evaluation, prescribed exercise, modification to reduce cardiac risks, education, and counseling.
The general outcomes of interest are OS, disease-specific survival, symptoms, and morbid events.
Once diagnosed with heart disease, a patient will require lifelong monitoring by a cardiologist.
Methodologically credible studies were selected using the following principles:
To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.
No RCTs evaluating the Pritikin Program were identified. Lakhani et al (2023) conducted a prospective, nonrandomized study that compared intensive cardiac rehabilitation with the Pritikin Program and traditional outpatient cardiac rehabilitation.22, The primary outcomes of interest were change in diet quality and quality of life from baseline to visit 24. There was a significant improvement in diet quality but not in quality of life between the Pritikin Program and traditional cardiac rehabilitation groups. Body mass index was also improved in patients who received intensive rehabilitation. Limitations of the study include a short follow-up and lack of data for cardiovascular outcomes.
Racette et al (2023) published 7-year outcomes from the first institution to implement the Pritiken Program.23, Retrospective data for 1,507 patients who received the intensive cardiac rehabilitation program and 456 patients who received traditional cardiac rehabilitation were compared. Outcomes of interest (eg, anthropometric measures, dietary patterns, 6-minute walk distance [6MWD], grip strength, and HRQoL) all improved with the Pritiken Program. Significant benefit of the Pritiken Program compared to traditional cardiac rehabilitation were noted for change in body weight (p<.0001), body mass index (p<.0001), waist circumference (p<.0001), and diet quality as measured by the Rate Your Plate score (p<.0001). There was no difference in 6MWD or grip strength between groups. Cardiovascular outcomes, including rehospitalization or mortality, were not assessed.
Study | Study Type | Country | Dates | Participants | Intensive cardiac rehabilitation | Traditional cardiac rehabilitation | Follow-Up |
Lakhani et al (2023)22, | Cohort | U.S. | 2017-2021 | Referred by a cardiologist for cardiac rehabilitation | n=230 | n=62 | 24 visits |
Racette et al (2022)23, | Cohort | U.S. | 2013-2019 | Enrolled in a cardiac rehabilitation program in the course of usual care | N=1,507 | N=456 | 72 sessions over 18 weeks; 7 year follow-up |
Study | Change in diet quality | Change in QOL | Change in body weight (kg) | Change in BMI (kg/m2) | Change in 6MWD (m) |
Lakhani et al (2023)22, | N=292 | N=292 | NR | NR | NR |
Intensive cardiac rehabilitation |
|
| NR | NR | NR |
Traditional cardiac rehabilitation |
|
| NR | NR | NR |
p-value | .001 | NS | NR | NR | NR |
Racette et al (2022)23, | NR | NR | N=1,963 | N=1,963 | N=1,963 |
Intensive cardiac rehabilitation | NR | NR | −1.4±2.8 | −0.5±1.0 | 46.4±57.8 |
Traditional cardiac rehabilitation | NR | NR | 0.1±3.2 | 0.1±1.1 | 44.4±58.9 |
p-value | NR | NR | <.001 | <.001 | .106 |
6MWD: 6-minute walk distance; BMI: body mass index; NR: not reported; NS: not significant; QOL: quality of life.
Section Summary: Pritikin Program
No RCTs have evaluated the Pritikin Program; 2 nonrandomized studies in patients with heart disease were identified. Conclusions cannot be drawn from this limited data on the impact on cardiovascular outcomes of intensive cardiac rehabilitation with the Pritikin Program compared with standard outpatient cardiac rehabilitation.
For individuals who have been diagnosed with heart disease and receive intensive cardiac rehabilitation with the Pritikin Program, the evidence includes 2 nonrandomized studies. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. Studies are needed that compare the impact of intensive cardiac rehabilitation using the Pritikin Program with standard outpatient cardiac rehabilitation programs for these outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Pritikin Program
PopulationReference No. 4Policy Statement | [ ] Medically Necessary | [X] Investigational |
The purpose of the Benson-Henry Institute Program in individuals who have been diagnosed with heart disease is to provide a treatment option that is an alternative to or an improvement on existing therapies.
The following PICO was used to select literature to inform this review.
The relevant population of interest is individuals with diagnosed heart disease.
The treatment being considered is the Benson-Henry Institute Program.
The Benson-Henry Institute Program is an intensive cardiac rehabilitation program based on effective exercise, a healthy diet, and a healthy mindset.
The comparator of interest is standard outpatient cardiac rehabilitation. Cardiac rehabilitation includes long-term programs that include medical evaluation, prescribed exercise, modification to reduce cardiac risks, education, and counseling.
The general outcomes of interest are OS, disease-specific survival, symptoms, and morbid events.
Once diagnosed with heart disease, a patient will require lifelong monitoring by a cardiologist.
Methodologically credible studies were selected using the following principles:
To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.
Zeng et al (2013) reported outcomes of a Medicare-sponsored demonstration of 2 intensive lifestyle modification programs in patients with symptomatic coronary heart disease: the Cardiac Wellness Program of the Benson-Henry Mind Body Institute and the Dr. Dean Ornish Program for Reversing Heart Disease.24, This analysis included 461 participants and 1,795 matched controls using Medicare claims data from 1998 to 2008. Four matched controls were sought for each participant from Medicare claims data, 2 of whom had received traditional cardiac rehabilitation within 12 months following their cardiac events (cardiac rehabilitation controls) and 2 of whom had not (non-cardiac rehabilitation controls). Outcomes included mortality rates during the 3 post-enrollment years, total hospitalizations, hospitalizations with a cardiac-related principal discharge diagnosis, and Medicare-paid costs of care. Of the 324 participants in the Benson-Henry Mind Body Medical Institute program analysis, the authors concluded that during the active intervention and follow-up years, total, cardiac, and non-cardiac hospitalizations were lower in the Benson-Henry program participants than their controls for each comparison (p<.001). The investigators further reported that after year 1, the mortality rate was 1.5% in the Benson-Henry program participants compared with 2.5% and 4.2%, respectively, in cardiac rehabilitation and non-cardiac rehabilitation controls. After year 3, comparable figures were 6.2% in Benson-Henry program participants, 10.5% in cardiac rehabilitation controls, and 11.0% in non-cardiac rehabilitation controls. These mortality differences for the Benson-Henry program participants reached borderline significance (p=.08).
Casey et al (2009) reported the results of a case series that evaluated the effects of an intensive cardiac rehabilitation program, incorporating components of the Benson-Henry Institute Cardiac Wellness Program at a single center.25, From 1997 to 2005, 637 patients with coronary artery disease were enrolled and completed the program, which consisted of 13 weekly 3 hour sessions with supervised exercise, relaxation techniques, stress management, and behavioral interventions. The mean age of participants was 63 years (range, 27 to 92 years); men comprised 72% of the study population. Results revealed significant improvements in clinical (blood pressure, lipids, weight, exercise conditioning, frequency of symptoms of chest pain, and shortness of breath) and psychological outcomes (general severity index, depression, anxiety, and hostility) (p<.0001) with the program.
No RCTs have evaluated the Benson-Henry Institute Program; a case-control study found the program participants to have lower total, cardiac, and non-cardiac hospitalizations during the active intervention and follow-up years compared to controls for each comparison. Additionally, program participants had lower mortality rates compared to controls; however, the mortality differences were borderline significant at year 3. A case series also demonstrated that the implementation of components of the Benson-Henry Institute program resulted in an improvement in clinical and psychological outcomes. Conclusions cannot be drawn from these data on the impact of intensive cardiac rehabilitation with the Benson Henry Institute program compared with standard outpatient cardiac rehabilitation.
For individuals who have been diagnosed with heart disease and receive intensive cardiac rehabilitation with the Benson-Henry Institute Program, the evidence includes a case-control study and case series. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. Studies are needed that compare the impact of intensive cardiac rehabilitation using the Benson-Henry Institute Program with standard outpatient cardiac rehabilitation programs. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Benson-Henry Institute Program
PopulationReference No. 5Policy Statement | [ ] Medically Necessary | [X] Investigational |
The purpose of outpatient cardiac rehabilitation is to provide a treatment option that is an alternative to or an improvement on standard management without outpatient cardiac rehabilitation.
The following PICO was used to select literature to inform this review.
The relevant population of interest is individuals with post-acute cardiac sequelae of SARS-CoV-2 infection or COVID-19. The Centers for Disease Control and Prevention define the post-acute period as symptoms persisting at 4 or more weeks following infection with SARS-CoV-2.26, The World Health Organization developed the following consensus case definition of 'post COVID-19 condition': individuals with "a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, cognitive dysfunction but also others and generally have an impact on everyday functioning. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time."27,
The treatment being considered is cardiac rehabilitation. Cardiac rehabilitation includes long-term programs that include medical evaluation, prescribed exercise, modification to reduce cardiac risks, education, and counseling.
The comparator of interest is standard management without cardiac rehabilitation. The following practices are currently being used to manage heart disease: medication, surgery, and medical devices.
The general outcomes of interest are OS, disease-specific survival, symptoms, and morbid events.
Once diagnosed with heart disease, a patient will require lifelong monitoring by a cardiologist.
Methodologically credible studies were selected using the following principles:
To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.
Reports of patient rehabilitation after COVID-19 recovery have largely been observational, without clearly identifiable cardiac rehabilitation components within multidisciplinary or cardiorespiratory rehabilitation programs.
No studies specifically assessing the efficacy of cardiac rehabilitation programs for post-acute cardiac sequelae of SARS-CoV-2 infection were identified.
No direct evidence on the efficacy of cardiac rehabilitation programs in patients with post-acute cardiac sequelae of SARS-CoV-2 infection was identified. Controlled prospective studies in well-defined patient populations with sufficient follow-up duration are necessary to evaluate net health outcomes.
For individuals who have heart disease due to post-acute sequelae of SARS-CoV-2 infection who receive cardiac rehabilitation in the outpatient setting, no relevant evidence was identified. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. Limited reports examining the outcomes of rehabilitation in patients with post-acute COVID-19 have not primarily focused on cardiac rehabilitation. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Post-Acute Cardiac Sequelae of SARS-CoV-2 Infection
PopulationReference No. 6Policy Statement | [ ] Medically Necessary | [X] Investigational |
Population Reference No. 7
The purpose of virtual cardiac rehabilitation in individuals who have been diagnosed with heart disease is to provide a treatment option that is an alternative to or an improvement on existing therapies.
The following PICO was used to select literature to inform this review.
The relevant population of interest is individuals with diagnosed heart disease.
The treatment being considered is virtual cardiac rehabilitation.
Virtual cardiac rehabilitation is HBCR delivered by virtual or remote interactions between patients and providers, including video conferencing, phone, email, text, smartphone applications, or wearable devices.
The comparator of interest is standard outpatient cardiac rehabilitation. Cardiac rehabilitation includes long-term programs that include medical evaluation, prescribed exercise, modification to reduce cardiac risks, education, and counseling.
The general outcomes of interest are OS, disease-specific survival, symptoms, and morbid events.
Once diagnosed with heart disease, a patient will require lifelong monitoring.
Methodologically credible studies were selected using the following principles:
To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
Studies with duplicative or overlapping populations were excluded.
Many meta-analyses/systematic reviews are available for virtual cardiac rehabilitation.28,29,30,31,32,33, In general, these reviews have found significant effects on physical activity, cardiovascular risk factors, and quality of life, but evidence for cardiovascular outcomes is limited.
A Cochrane systematic review by McDonagh et al (2023) compared home-based cardiac rehabilitation (including a variety of virtual methods) with center-based rehabilitation.34, A total of 24 RCTs were included (N=3046). The meta-analysis did not find a significant difference between home and and center-based rehabilitation up to 12 months in the outcomes of: total mortality (risk ratio, 1.19; 95% CI, 0.65 to 2.16) or exercise capacity (standardized mean difference, -0.10; 95% CI, -0.24 to 0.04). The authors concluded that home rehabilitation with or without virtual platforms results in similar clinical outcomes; however, the analysis does not provide adequate information on specific virtual rehabilitation programs.
The analysis by Cruz-Cobo et al (2022) included 20 randomized studies (N=4,535) of mobile health interventions in patients who had experienced a coronary event.31, Beneficial effects of mobile health interventions were found for exercise capacity, physical activity, adherence to treatment, and quality of life. All-cause hospital readmission (p=.04) and hospital readmission for cardiovascular causes (p=.05) were statistically lower in the mobile health intervention group compared to the control group, but these may not be clinically relevant differences (point estimates for actual risk differences were -0.03 and -0.04, respectively). There was no difference between groups in mortality. A major limitation of this study is lack of clarity of how many individuals received mobile health interventions for the purpose of cardiac rehabilitation.
Zhou et al (2023) conducted a systematic review of smartphone-assisted cardiac rehabilitation compared with usual cardiac rehabilitation.35, A total of 14 RCTs (N=1962) were included and key outcomes included peak oxygen update, 6MWD, complicance, and body mass index (BMI). There were no significant differences in terms of 6MWD (weighted mean difference [WMD], 12.88; 95% CI, -0.82 to 26.57) or BMI (WMD, -0.14; 95% CI, -0.34 to 0.06) between groups; however, peak oxygen update (WMD, 1.32; 95% CI, 0.82 to 1.81) and compliance (WMD, 1.62; 95% CI, 1.21 to 2.17) were improved with smartphone-assisted rehabilitation.
Numerous RCTs with virtual cardiac rehabilitation have been published.36,37,38,39,40,41,42,43,44,45,46, Of these, only 2 have reported results for cardiovascular outcomes of interest. Indraratna et al (2022) found that unplanned hospital readmissions and cardiac readmissions were significantly lower with a smartphone-based intervention to facilitate the transition to outpatient cardiac care (including rehabilitation) compared to usual care among 164 patients being discharged after hospitalization for acute coronary syndrome or heart failure.39, However, only 100 patients in the study received cardiac rehabilitation after discharge and rehospitalization rates were not provided for this cohort alone. Other limitations of this study include short duration of follow-up (6 months) and that enrollment was terminated in March 2020 so the study may not reflect how usual care is delivered in the post-COVID-19 pandemic era. Piotrowicz et al (2020) conducted a 9-week RCT of telerehabilitation compared to usual care in 850 patients with heart failure.41, Both groups had a median follow-up of 793 days. The primary outcome (days alive and out of the hospital through end of follow-up) was similar between groups (median, 775 days [telerehabilitation] vs. 776 days [usual care]). There was also no difference between telerehabilitation and usual care in all-cause hospitalization (HR, 0.913; 95% CI, 0.762 to 1.093), cardiovascular hospitalization (HR, 0.837; 95% CI, 0.667 to 1.050), all-cause mortality (HR, 1.035; 95% CI, 0.706 to 1.517), or cardiovascular mortality (HR, 0.985; 95% CI, 0.619 to 1.569). Since the study only included patients with heart failure, the results may not be applicable to patients with other forms of heart disease. Other limitations include a lack of power for hospitalization and mortality outcomes, and that the cardiac monitoring device used in the study may not reflect the effect of video- or smartphone-based virtual rehabilitation methods used in current practice.
Nkonde-Price et al (2022) conducted a retrospective study of virtual cardiac rehabilitation compared to traditional cardiac rehabilitation in a cohort of 2556 patients with cardiovascular disease.47, Virtual cardiac rehabilitation consisted of home-based cardiac rehabilitation using a mobile phone application linked to a wearable smartwatch, self-directed exercise sessions, weekly nurse phone calls, and health education for 8 weeks. The primary outcome, all-cause hospitalization during 12 months of follow-up, was lower in patients who experienced the virtual cardiac rehabilitation program compared to traditional outpatient cardiac rehabilitation (14.8% vs. 18.1%; OR, 0.79; 95% CI, 0.64 to 0.97; p=.03). There was no difference between groups in 30-day or 90-day all-cause or cardiovascular hospitalization. Mortality was not addressed.
Systematic reviews and RCTs suggest that virtual cardiac rehabilitation may have similar effects on cardiovascular outcomes compared to standard outpatient cardiac rehabilitation, but evidence about the effect on hospital readmission is inconsistent. One RCT in patients with heart failure found no difference between virtual cardiac rehabilitation and standard outpatient cardiac rehabilitation on the primary outcome of days alive and out of the hospital. No RCTs have been adequately powered to detect or reported a difference in all-cause mortality or cardiovascular mortality.
For individuals who have been diagnosed with heart disease and receive virtual cardiac rehabilitation, the evidence includes systematic reviews/meta-analyses, RCTs, and observationalr studies. Relevant outcomes are OS, disease-specific survival, symptoms, and morbid events. Meta-analyses have found beneficial effects of virtual cardiac rehabilitation on physical activity and quality of life, but not on cardiovascular hospitalization or mortality. The few available prospective randomized studies have conflicting findings on the effect of virtual cardiac rehabilitation compared to traditional outpatient cardiac rehabilitation for hospital readmission. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Virtual Cardiac Rehabilitation
PopulationReference No. 7Policy Statement | [ ] Medically Necessary | [X] Investigational |
SUPPLEMENTAL INFORMATION
The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.
The 2022 American College of Cardiology (ACC) and the American Heart Association (AHA) heart failure guidelines recommend rehabilitation for Stage C heart failure stating, "In patients with HF, a cardiac rehabilitation program can be useful to improve functional capacity, exercise tolerance, and health-related QOL."48,In 2023, theACC/AHA published a statement on supervised exercise training specific to patients with chronic heart failure with preserved ejection fraction (HFpEF) and concluded, "data reviewed herein demonstrate a comparable or larger magnitude of improvement in exercise capacity from supervised exercise training in patients with chronic HFpEF compared with those with heart failure with reduced ejection fraction."49,
In 2007, the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation issued a consensus statement on the core components of cardiac rehabilitation programs.2, The core components included patient assessment before beginning the program, nutritional counseling, weight management, blood pressure management, lipid management, diabetes management, tobacco cessation, psychosocial management, physical activity counseling, and exercise training. Programs that only offered supervised exercise training were not considered cardiac rehabilitation. The guidelines specified the assessment, interventions, and expected outcomes for each of the core components. For example, symptom-limited exercise testing before exercise training was strongly recommended. The guidelines did not specify the optimal overall length of programs or the number or duration of sessions.
In 2019, the American Heart Association, with the American Association of Cardiovascular and Pulmonary Rehabilitation and the American College of Cardiology, released a scientific statement on home-based cardiac rehabilitation (HBCR).50, They make the following suggestions for healthcare providers:
Recommend center-based cardiac rehabilitation (CBCR) to all eligible patients.
As an alternative, recommend HBCR to clinically stable low- and moderate-risk patients who cannot attend CBCR.
Design and test HBCR “using effective processes of care for CVD [cardiovascular disease] secondary prevention.”
For healthcare organizations, develop and support the following:
Maximization of cardiac rehabilitation (CR) referrals
High-quality CBCR and HBCR programs “using evidence-based standards and guidelines, strategies to maximize patient adherence both in the shorter and longer-term, and outcome tracking methods to help promote continuous quality improvement.”
“Testing and implementation of an evidence-based hybrid approach to CR" that are optimized for each patient and that "promote long-term adherence and favorable behavior change.”
For CR professionals, “work with other healthcare professionals and policymakers to implement additional research and...expand the evidence base for HBCR.”
The guideline does not use the terminology "virtual" cardiac rehabilitation, but it states that electronic tools such as text messaging, smartphone applications, and wearable sensors may allow patients to follow personalized recommendations for exercise, dietary, and behavioral interventions, and thus expand the number of patients who can participate in cardiac rehabilitation. Other benefits of technology-assisted HBCR include greater patient engagement and patient-provider communication. The panel stated that studies were needed regarding the effect of technology-assisted HBCR on outcomes.
Not applicable.
Since 1989, Medicare has had a national coverage determination (NCD) for cardiac rehabilitation. The NCD was retired in April 2023. CMS periodically retires NCDs that no longer contain clinically pertinent and/or current information or no longer reflect current medical practice. In the absence of NCDs, coverage determinations are made by the Medicare Administrative Contractors (MACs) under section 1862(a)(1)(A) of the Social Security Act. 51,
In October 2020, virtual cardiac rehabilitation and intensive cardiac rehabilitation were added to the list of telehealth services that Medicare would cover during the COVID-19 public health emergency.52, Virtual cardiac rehabilitation will continue to be covered through the end of 2024.53,54,
In January 2010, Medicare added intensive cardiac rehabilitation as a benefit. Intensive cardiac rehabilitation programs must be approved by Medicare on an individual basis.55,
The national coverage determination described intensive cardiac rehabilitation in the following manner:
“Intensive cardiac rehabilitation (ICR) refers to a physician-supervised program that furnishes cardiac rehabilitation services more frequently and often in a more rigorous manner. As required by §1861(eee)(4)(A) of the Social Security Act (the Act), an ICR program must show, in peer-reviewed published research, that it accomplished 1 or more of the following for its patients: (1) positively affected the progression of coronary heart disease; (2) reduced the need for coronary bypass surgery; and, (3) reduced the need for percutaneous coronary interventions. The ICR program must also demonstrate through peer-reviewed published research that it accomplished a statistically significant reduction in 5 or more of the following measures for patients from their levels before cardiac rehabilitation services to after cardiac rehabilitation services: (1) low density lipoprotein; (2) triglycerides; (3) body mass index; (4) systolic blood pressure; (5) diastolic blood pressure; and, (6) the need for cholesterol, blood pressure, and diabetes medications. Individual ICR programs must be approved through the national coverage determination process to ensure that they demonstrate these accomplishments.”
In 2010, the Centers for Medicare & Medicaid Services also issued 2 decision memos on specific programs. One stated that the Ornish Program for Reversing Heart Disease met the intensive cardiac rehabilitation program requirements and was included on the list of approved intensive cardiac rehabilitation programs.55, It provided the following description of the Ornish Program: “The Ornish Program for Reversing Heart Disease (also known as the Multisite Cardiac Lifestyle Intervention Program, Multicenter Cardiac Lifestyle Intervention Program and the Lifestyle Heart Trial program) … incorporates comprehensive lifestyle modifications including exercise, a low-fat diet, smoking cessation, stress management training, and group support sessions. Over the years, the Ornish program has been refined but continues to focus on these specific risk factors.”
The other stated that the Pritikin Program met program requirements and was included on the list of approved intensive cardiac rehabilitation programs.56, As described in the decision memo: “The Pritikin program (also known as the Pritikin Longevity Program) evolved into a comprehensive program that is provided in a physician’s office and incorporates a specific diet (10% to 15% of calories from fat, 15% to 20% from protein, 65% to 75% from complex carbohydrates), exercise and counseling lasting 21 to 26 days. An optional residential component is also available for participants.”
In 2014, Centers of Medicare & Medicaid Services issued another decision memo on the Benson-Henry Institute Cardiac Wellness Program.57, The memo stated that "the evidence is sufficient to expand the intensive care rehabilitation benefit to include the Benson-Henry Institute Cardiac Wellness Program. The Cardiac Wellness Program is a multicomponent intervention program that includes supervised exercise, behavioral interventions, and counseling, and is designed to reduce cardiovascular risk and improve health outcomes."
Some currently ongoing and unpublished trials that might influence this review are listed in Table 9.
NCT No. | Trial Name | Planned Enrollment | Completion Date |
Ongoing | |||
NCT06077201 | Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions | 375 | Oct 2026 |
NCT05933083 | MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation | 516 | Oct 2027 |
NCT05972070 | Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence | 500 | Nov 2023 |
NCT04245813 | Effectiveness of a Cardiac Rehabilitation Program in Patients With Heart Failure | 144 | May 2023 |
NCT02984449 | Preventive Heart Rehabilitation in Patients Undergoing Elective Open Heart Surgery to Prevent Complications and to Improve Quality of Life (Heart-ROCQ) - A Prospective Randomized Open Controlled Trial, Blinded End-point (PROBE) | 350 | Aug 2025 |
NCT05270993 | An Integrative Cardiac Rehabilitation Employing Smartphone Technology (iCREST) for Patients With Post-myocardial Infarction: A Randomized Controlled Trial | 124 | Dec 2023 |
NCT05689385 | The Effectiveness of eHealth-based Cardiac Rehabilitation in Post-myocardial Infarction Patients:a Randomized Controlled Trial | 150 | Dec 2024 |
NCT05610358 | Efficacy of Smartphone Application Based Rehabilitations in Patients With Chronic Respiratory or Cardiovascular Disease | 162 | Dec 2024 |
NCT02791685 | Smartphone Delivered In-home Cardiopulmonary Rehabilitation | 300 | Dec 2026 |
NCT: national clinical trial.
CODES
Codes | Number | Description |
---|---|---|
CPT | 93015 | Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; with physician supervision, with interpretation and report |
93016 | Same as 93015, but with physician supervision only, and without interpretation and report | |
93017 | Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report | |
93018 | Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only | |
93797 | Physician or other qualified health care professional services for outpatient cardiac rehab; without continuous ECG monitoring (per session) | |
93798 | ; with continuous ECG monitoring (per session) | |
HCPCS | G0422 | Intensive cardiac rehabilitation; with or without continuous ECG monitoring with exercise, per session |
G0423 | Intensive cardiac rehabilitation; with or without continuous ECG monitoring; without exercise, per session | |
S9472 | Cardiac rehabilitation program, nonphysician provider, per diem | |
ICD-10-CM | I20.81-I20.9 | Angina pectoris, other/unspecified code range (new codes eff 10/01/2023) |
I21.01-I21.4 | ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction code range | |
I50.1-I50.9 | Heart failure code range | |
Z94.1 | Heart transplant status | |
Z94.3 | Heart and lungs transplant status | |
Z95.1 | Presence of aortocoronary bypass graft | |
Z95.2-Z95.4 | Presence of heart valve code range | |
Z95.5 | Presence of coronary angioplasty implant and graft | |
Z98.61 | Coronary angioplasty status | |
ICD-10-PCS | Not applicable. Policy is only for outpatient services. | |
Type of Service | Medical | |
Place of Service | Outpatient |
POLICY HISTORY
Date | Action | Description |
04/09/24 | Annual Review | Policy updated with literature review through January 23, 2024; references added. Investigational policy statement added for all other indications, including post-acute sequelae of SARS-CoV-2 infection. |
04/04/23 | Annual Review | Policy updated with literature review through February 7, 2023; references added. Added PICO and investigational policy statement for virtual cardiac rehabilitation. |
04/04/22 | Annual Review | Policy updated with literature review through February 3, 2022; reference added. Policy statements unchanged. |
04/07/21 | Annual Review | Policy updated with literature review through January 20, 2021; references added. Added PICO and investigational policy statement for intensive cardiac rehabilitation with the Benson-Henry Institute Program. |
04/13/20 | Annual Review | Policy updated with literature review through January 13, 2020; reference added. Policy statements unchanged. |
04/30/19 | Annual Review | Policy updated with literature review through January 6, 2019; references added. Policy statements unchanged. |
04/12/18 | Annual Review | Policy updated with literature review through January 26, 2018; references 13-14, and 16 added. Minor edit to the Policy section; policy statements otherwise unchanged. |
06/15/17 | | Policy updated with literature review through May 31, 2017; references 11, 14-16, and 22-23 added. Statement added that Intensive cardiac rehabilitation with the Pritikin Program or the Ornish Program is considered investigational. |
04/18/16 | Created | New policy |
PAYMENT POLICY GUIDELINES
Applicable Specialties | Internal Medicine,Family Medicine, Cardiology, Geriatrics | |
Preauthorization required | [X] Yes | [ ] No |
Preauthorization requirements | Individual with history of:
| |
Place of Service | Outpatient, medically supervised cardiac rehabilitation program | |
Age Limit | No age limit | |
Frequency | Program include 3 sessions per week up to 12 weeks. Programs should start within 90 days of the cardiac event and be completed within 6 months of the cardiac event. | |
Frequency Limit | N/A |
ADMINISTRATIVE EVALUATION
As established by the policy.
ECONOMIC IMPACT
[ ] YES | [X] NO |
Description: |
INTERQUAL CRITERIA
[ ] YES If Yes, describe the comparison between Interqual criteria and this Policy | [X] NO |
DESCRIBE THE COMPARISON BETWEEN INTERQUAL CRITERIA AND THIS POLICY: |
POLICY CATEGORIZATION
[ ] LOCAL | [X] BCBSA |
SPECIFY RATIONALE: |
Approved By: |